Evidence map›Paper›PMID 34389608›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Interpreting the Complex Landscape of Immune-Tumor Interface.

W Fraser Symmans

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Clinical Prognostic Value of theFrontiers in molecular biosciences · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

W Fraser SymmansDepartments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. fsymmans@mdanderson.org.ORCID 0000-0002-1526-184X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predictive biomarkers for immune therapy must address a complex interface between the immune system and triple-negative breast cancer and still be technically reliable for diagnostic use. Two recent articles describe the assessment of spatial heterogeneity using digital methods that promise to improve the quantification of immune infiltrate or molecular targets.

Indexed as

Triple Negative Breast NeoplasmsBiomarkersHumansBiomarkers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.